Key result
Intravenous infusion of free n-3 PUFA prevented ischemia-induced ventricular fibrillation in 76.9% (10 of 13) of susceptible dogs during exercise-plus-ischemia tests (P < 0.005).
Why the study?
Does intravenous n-3 PUFA prevent ischemia-induced ventricular fibrillation in a canine model?
Does intravenous n-3 PUFA prevent ischemia-induced ventricular fibrillation in a canine model?
Intravenous n-3 PUFA significantly prevents ischemia-induced ventricular fibrillation in a canine model, accompanied by favorable electrophysiological changes.
Answers are grounded in this paper and cite their sources.
Supports antiarrhythmic effects of n-3 PUFA in canine ischemia model; leaves open clinical translation to human sudden death prevention.
The objective of this study was to obtain functional information associated with the prevention by n-3 polyunsaturated fatty acids (PUFA) of ischemia-induced fatal cardiac ventricular arrhythmias in the intact, conscious, exercising dog. Thirteen dogs susceptible to ischemia-induced ventricular fibrillation were prepared surgically by ligation of their anterior descending left coronary artery and placement of an inflatable cuff around their left circumflex artery. After 4 wk of recovery, exercise-plus-ischemia tests were performed without and then with an intravenous infusion of an emulsion of free n-3 PUFA just prior to occluding the left circumflex artery while the animals were running on a treadmill. One week later the exercise-plus-ischemia test was repeated but with a control infusion replacing the emulsion of n-3 PUFA. The infusion of the free n-3 PUFA in quantities of 1.0 to 10 g prevented ventricular fibrillation in 10 of the 13 dogs tested (P < 0.005), apparently without esterification of the PUFA into membrane phospholipids. The antiarrhythmic effect of the n-3 PUFA was associated with slowing of the heart rate, shortening of the QT-interval (electrical action potential duration), reduction of left ventricular systolic pressure, and prolongation of the electrocardiographic atrial-ventricular conduction time (P-R interval). These effects are comparable with those we have reported in studies with cultured neonatal rat cardiac myocytes.
No takes yet. Share an insight, caveat, or question.
Billman et al. (1997) studied Ischemia-induced ventricular fibrillation (n=13). Intravenous infusion of free n-3 PUFA vs. Control infusion was evaluated on Prevention of ventricular fibrillation (p=< 0.005). Intravenous infusion of free n-3 PUFA prevented ischemia-induced ventricular fibrillation in 76.9% (10 of 13) of susceptible dogs during exercise-plus-ischemia tests (P < 0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: